Collectively, these findings shed light on previously unexplored aspects of SF3A2's role in CRC, suggesting its potential as a target for therapeutic intervention and as a novel biomarker for predicting responses to immunotherapy in CRC patients. The gene discussed is SF3A2; the disease is colorectal carcinoma.